Integra Therapeutics and Caszyme receive €1-million Eurostars grant
Integra Therapeutics has been awarded €1-million grant from Eurostars, the largest funding programme of the European Commission that supports innovative SMEs in developing collaborative transnational projects geared towards the market. The company applied for the call as part of a consortium with Caszyme, a Lithuanian company that specialises in CRISPR technology and molecular tools development […]
Integra Therapeutics chosen one of the ten most disruptive companies by the Government of Catalonia
Integra Therapeutics is now one of the Catalonia Exponential Leaders, an initiative promoted by ACCIÓ (Government of Catalonia) to identify and raise awareness of business projects that can adapt, transform and have a global impact on the most significant economic and social areas for the future. The distinction has announced today at the 2022 Exponential […]
Integra Therapeutics receives Catalan Society of Biology Award 2022
Integra Therapeutics has received the Catalan Society of Biology (SCB) Award for best innovative start-up of 2022 for developing the next-generation of gene writing tools for therapeutic purposes in the field of life sciences. The SCB Board of Directors recognised Integra Therapeutics’ innovative technology, the benefit to society and the team‘s ability to bring the […]
Marc Güell, new member of Young Academy of Spain
Dr Marc Güell, co-founder of Integra Therapeutics and principal investigator of the Translational Synthetic Biology Laboratory at Pompeu Fabra University (UPF), has been made a member of the Young Academy of Spain (AJE) after a selection process with 87 candidates. He will belong to the AJE for five years. This makes Dr Güell an Academic […]
Avencia Sánchez-Mejías receives Women and Leadership Award
Dr Avencia Sánchez-Mejías, co-founder and CEO of Integra Therapeutics, won the first edition of the Women and Leadership Award promoted by Deusto Business School, Cinco Días and Banco Santander to boost and raise awareness of the talent of female executives at companies and in entrepreneurship. The ceremony was held on 2 June at the business […]
Integra Therapeutics appoints Mark Bonyhadi as new independent director
Integra Therapeutics announced today that Dr Mark Bonyhadi has been appointed to its Board of Directors as an independent director. Dr Bonyhadi has more than 30 years of experience in biopharmaceutical leadership roles in the US, specifically in developing commercially viable approaches to take cell and gene therapies and regenerative medicine from the lab to […]
Integra Therapeutics completes the €6-million seed round with the addition of Columbus Venture Partners
Integra Therapeutics has closed an additional €1.5-million investment from venture capital firm Columbus Venture Partners. This investment comes on top of the €4.5 million Integra Therapeutics raised last December from AdBio Partners, Invivo Capital and Takeda Ventures and completes its seed round in line with the company’s set goals. The new funds will go to […]
Integra Therapeutics appoints recognized geneticist George Church to its Scientific Advisory Board
Integra Therapeutics announced today the appointment of Professor George Church to its Scientific Advisory Board (SAB). Prof. George Church is a pioneering scientist in reading and writing DNA. He developed the first direct genomic sequencing method and helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005 and demonstrated that […]
Integra Therapeutics at ‘CRISPR News Medicine’
CRISPR News Medicine publishes an article entitled Adaptation of jumping gene boosts CRISPR-Cas gene-writing technology to new heights about new FiCAT platform developed by Integra Therapeutics. By Henri van de Vrugt
Integra Therapeutics at ‘Pharmaceutical Technology’
Pharmaceutical Technology review publishes an article entitled Integra Therapeutics Q&A: building next-generation gene editing tools where our CEO Avencia Sánchez-Mejías discusses how the company’s gene writing tool could improve advanced therapies for patients. By Darcy Jimenez